SG11202106855YA - Gene therapy constructs for treating wilson disease - Google Patents

Gene therapy constructs for treating wilson disease

Info

Publication number
SG11202106855YA
SG11202106855YA SG11202106855YA SG11202106855YA SG11202106855YA SG 11202106855Y A SG11202106855Y A SG 11202106855YA SG 11202106855Y A SG11202106855Y A SG 11202106855YA SG 11202106855Y A SG11202106855Y A SG 11202106855YA SG 11202106855Y A SG11202106855Y A SG 11202106855YA
Authority
SG
Singapore
Prior art keywords
gene therapy
wilson disease
therapy constructs
treating wilson
treating
Prior art date
Application number
SG11202106855YA
Other languages
English (en)
Inventor
Christine Livingston
Samuel Wadsworth
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of SG11202106855YA publication Critical patent/SG11202106855YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202106855YA 2019-01-04 2020-01-03 Gene therapy constructs for treating wilson disease SG11202106855YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788324P 2019-01-04 2019-01-04
US201962834830P 2019-04-16 2019-04-16
PCT/US2020/012131 WO2020142653A1 (en) 2019-01-04 2020-01-03 Gene therapy constructs for treating wilson disease

Publications (1)

Publication Number Publication Date
SG11202106855YA true SG11202106855YA (en) 2021-07-29

Family

ID=69528954

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106855YA SG11202106855YA (en) 2019-01-04 2020-01-03 Gene therapy constructs for treating wilson disease

Country Status (18)

Country Link
US (1) US20220090131A1 (es)
EP (2) EP3906066B1 (es)
JP (2) JP2022516283A (es)
KR (1) KR20210112339A (es)
CN (1) CN113518628A (es)
AU (1) AU2020204679A1 (es)
BR (1) BR112021013140A2 (es)
CA (1) CA3124880A1 (es)
CO (1) CO2021010088A2 (es)
DK (1) DK3906066T3 (es)
ES (1) ES2970216T3 (es)
FI (1) FI3906066T3 (es)
HR (1) HRP20231750T1 (es)
IL (1) IL284554A (es)
MX (1) MX2021008135A (es)
PT (1) PT3906066T (es)
SG (1) SG11202106855YA (es)
WO (1) WO2020142653A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019013245A2 (pt) 2016-12-30 2020-02-11 The Trustees Of The University Of Pennsylvania Terapia gênica para tratamento da doença de wilson
WO2019195449A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
MX2021011468A (es) 2019-03-21 2021-12-15 Vectores de virus adenoasociados recombinantes.
CA3140049A1 (en) * 2019-05-14 2020-11-19 Duke University Compositions and methods for the treatment of atpase-mediated diseases
WO2021076925A1 (en) 2019-10-17 2021-04-22 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
CN115216481A (zh) * 2021-04-21 2022-10-21 四川至善唯新生物科技有限公司 一种表达量提高的截短型atp7b基因及其应用
CN113694218A (zh) * 2021-08-30 2021-11-26 昆明理工大学 一种atp7b基因p992l突变的基因修复治疗载体
WO2023108130A2 (en) * 2021-12-10 2023-06-15 Aavantibio, Inc. Compositions comprising kozak sequences selected for enhanced expression
AU2022407655A1 (en) * 2021-12-10 2024-06-20 Aavantibio, Inc. Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
SG157224A1 (en) 2001-11-13 2009-12-29 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
EP1453547B1 (en) 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
EP2281877A3 (en) 2003-05-21 2011-06-01 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
DK3211085T3 (da) 2003-09-30 2021-06-21 Univ Pennsylvania Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
DK2359867T3 (en) 2005-04-07 2015-01-05 Univ Pennsylvania A method for increasing an AAV vector function
EP2242840B1 (en) 2008-01-29 2019-07-24 Applied Genetic Technologies Corporation Recombinant adeno-associated virus production using bhk cells in suspension
WO2010114948A2 (en) 2009-04-02 2010-10-07 University Of Florida Research Foundation, Inc. An inducible system for highly efficient production of recombinant adeno-associated virus (raav) vectors
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
IN2012DN06629A (es) 2010-01-28 2015-10-23 Philadelphia Children Hospital
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
DK3137497T3 (da) * 2014-05-02 2021-07-12 Genzyme Corp Aav-vektorer til retinal- og cns-genterapi
WO2016049230A1 (en) 2014-09-24 2016-03-31 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
PL3233130T3 (pl) * 2014-12-17 2021-11-22 Fundacion Para La Investigacion Medica Aplicada Konstrukty kwasów nukleinowych i wektory do terapii genowej do zastosowania w leczeniu choroby wilsona
BR112019013245A2 (pt) * 2016-12-30 2020-02-11 The Trustees Of The University Of Pennsylvania Terapia gênica para tratamento da doença de wilson
WO2023230466A1 (en) * 2022-05-23 2023-11-30 Lutsenka Svetlana Compositions and methods for treating wilson's disease

Also Published As

Publication number Publication date
EP3906066A1 (en) 2021-11-10
IL284554A (en) 2021-08-31
HRP20231750T1 (hr) 2024-05-24
JP2024054426A (ja) 2024-04-16
EP4269579A2 (en) 2023-11-01
AU2020204679A1 (en) 2021-07-15
KR20210112339A (ko) 2021-09-14
PT3906066T (pt) 2024-02-06
TW202043479A (zh) 2020-12-01
FI3906066T3 (fi) 2024-01-30
JP2022516283A (ja) 2022-02-25
ES2970216T3 (es) 2024-05-27
DK3906066T3 (da) 2024-02-05
CN113518628A (zh) 2021-10-19
BR112021013140A2 (pt) 2021-11-30
EP3906066B1 (en) 2023-11-01
US20220090131A1 (en) 2022-03-24
CO2021010088A2 (es) 2021-09-20
WO2020142653A1 (en) 2020-07-09
MX2021008135A (es) 2021-08-11
CA3124880A1 (en) 2020-07-09
EP4269579A3 (en) 2024-01-24

Similar Documents

Publication Publication Date Title
IL284554A (en) Structures for gene therapy to treat Wilson's disease
EP3562514A4 (en) GENE THERAPY TO TREAT WILSON'S DISEASE
IL286825A (en) Gene therapy for eye pathologies
IL279918A (en) Gene therapy vectors for the treatment of Danon disease
EP3796891A4 (en) THERAPEUTIC CONSTRUCTIONS FOR THE TREATMENT OF CANCER
IL279685A (en) Gene therapy
IL285238A (en) Gene therapy vectors for the treatment of Danon disease
IL289667A (en) Cardiac aav gene therapy for cardiomyopathy in humans
GB202114972D0 (en) Gene therapy
EP3720509A4 (en) GLOBING THERAPY FOR THE TREATMENT OF HEMOGLOBINOPATHIES
HK1253299A1 (zh) 一種通過基因治療治療眼疾病的改進方法
IL261292B2 (en) Gene therapy for the treatment of retinal degeneration
GB201522416D0 (en) Wilson's disease gene therapy
GB202003618D0 (en) Gene Therapy
GB201905301D0 (en) Gene therapy
IL276701A (en) Oligonucleotide therapy for Wilson's disease
IL306119A (en) Gene therapy for the treatment of beta-hemoglobinopathies
TWI848038B (zh) 用於治療威爾森氏症之基因療法構築體
GB201802326D0 (en) Gene therapy
IL286099A (en) Methods of treating the disease using levoketoconazole
GB201817469D0 (en) Gene therapy for retinal disease
GB202003109D0 (en) Gene therapy
GB202002202D0 (en) Gene therapy
EP3781130A4 (en) THERAPEUTIC CONSTRUCTS FOR TREATMENT OF CANCER
EP3760209C0 (en) GENE THERAPY SPECIFIC TO THE SITE OF AN ISCHEMIC INJURY